Albuterol Sulfate HFAalbuterol

According to the FDA label: Albuterol tablets, USP are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.

83,879 adverse event reports submitted to the FDA (2004–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Albuterol Sulfate HFA in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Albuterol Sulfate HFA adverse event reports by reporter sex
SexReports
Female43,539
Male22,990
Unknown51

By Age Group

View age group data as a table
Albuterol Sulfate HFA adverse event reports by reporter age group
Age groupReports
0-172,968
18-343,575
35-495,492
50-6411,591
65-748,944
75+7,039

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Albuterol Sulfate HFA. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Albuterol Sulfate HFA adverse event reports by reported outcome
OutcomeReports
Non-Serious49,292
Other Serious24,006
Hospitalization17,420
Death3,842
Life-Threatening1,472
Disability1,207

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Albuterol Sulfate HFA. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Albuterol Sulfate HFA adverse event reports by year
YearReports
2004280
2005269
200675
2007100
2008346
2009162
2010191
2011355
2012502
2013549
2014676
20151,256
20162,276
20171,663
20181,902
20192,897
20206,511
20218,623
20229,717
202312,690
202414,905
202514,825
2026 (partial)3,109

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Albuterol Sulfate HFA

In FDA adverse event reports that mention Albuterol Sulfate HFA, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026